ストックスクリーナーアプリを入手
2.05
5.67%
0.11
アフターアワーズ：
2.06
0.01
+0.49%
前日終値:
$1.94
開ける：
$2
24時間の取引高:
1.38M
Relative Volume:
0.82
時価総額：
$148.85M
収益：
-
当期純損益:
$-192.96M
株価収益率:
-0.6212
EPS:
-3.3
ネットキャッシュフロー:
$-167.04M
1週間 パフォーマンス:
-11.26%
1か月 パフォーマンス:
-8.07%
6か月 パフォーマンス:
-10.87%
1年 パフォーマンス:
-4.21%
1日の値動き範囲:
$1.96
$2.13
1週間の範囲:
$1.91
$2.30
52週間の値動き範囲:
$1.67
$11.48
Ventyx Biosciences Inc Stock (VTYX) Company Profile
名前
Ventyx Biosciences Inc
セクター
電話
(858) 945-2393
住所
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
VTYX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VTYX
Ventyx Biosciences Inc
|
2.05 | 148.85M | 0 | -192.96M | -167.04M | -3.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-03-12 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-03-12 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-11-07 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-11-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-07 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-11-07 | ダウングレード | Stifel | Buy → Hold |
| 2023-11-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-06-14 | 再開されました | Credit Suisse | Outperform |
| 2023-03-21 | 開始されました | Wells Fargo | Overweight |
| 2022-12-19 | 開始されました | Goldman | Buy |
| 2022-11-17 | 開始されました | Morgan Stanley | Overweight |
| 2022-09-07 | 開始されました | Stifel | Buy |
| 2022-09-01 | 開始されました | H.C. Wainwright | Buy |
| 2022-05-09 | 開始されました | Credit Suisse | Outperform |
| 2022-03-31 | 開始されました | Canaccord Genuity | Buy |
| 2022-02-01 | 開始されました | Oppenheimer | Outperform |
| 2021-11-15 | 開始されました | Jefferies | Buy |
| 2021-11-15 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Ventyx Biosciences Inc (VTYX) 最新ニュース
Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) high institutional ownership speaks for itself as stock continues to impress, up 10% over last week - Simply Wall St
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Acquired by Barclays PLC - Defense World
JPMorgan Chase & Co. Has $2.20 Million Holdings in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
What is HC Wainwright’s Estimate for VTYX FY2024 Earnings? - Defense World
HC Wainwright Analysts Increase Earnings Estimates for VTYX - MarketBeat
FY2029 Earnings Estimate for VTYX Issued By HC Wainwright - Defense World
Research Analysts Set Expectations for VTYX FY2029 Earnings - MarketBeat
Ventyx Biosciences Discloses Preliminary 2024 Financials and Pipeline Strategy - Defense World
Ventyx Biosciences highlights its 2025 pipeline strategy - Yahoo Finance
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Sold by Jane Street Group LLC - Defense World
Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio - GlobeNewswire
Ventyx Biosciences advances NLRP3 inhibitor trials By Investing.com - Investing.com Canada
HC Wainwright Reaffirms Neutral Rating for Ventyx Biosciences (NASDAQ:VTYX) - MarketBeat
Ventyx Biosciences highlights 2025 pipeline strategy and provides clinical updates; shares rise - MSN
Ventyx Biosciences Unveils 2025 Pipeline and Clinical Updates - TipRanks
Ventyx Biosciences advances NLRP3 inhibitor trials - Investing.com
Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on Its Nlrp3 Inhibitor Portfolio - Marketscreener.com
Ventyx Biosciences Inc’s (VTYX) -10.71% Retreat Justifies A Second Look - Stocks Register
We're Keeping An Eye On Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate - Yahoo Finance
Barclays PLC Increases Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Geode Capital Management LLC Has $3.03 Million Stock Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
State Street Corp Acquires 9,783 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Ventyx Biosciences chief scientific officer sells $49,840 in stock By Investing.com - Investing.com Australia
Ventyx Biosciences chief scientific officer sells $49,840 in stock - Investing.com India
John Nuss Sells 21,119 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) Stock - MarketBeat
Ventyx Biosciences director Sheila Gujrathi buys $300,573 in stock - Investing.com India
Sheila Gujrathi Buys 130,000 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) Stock - MarketBeat
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Insider John Nuss Sells 13,161 Shares - MarketBeat
Ventyx Biosciences' chief scientific officer sells $29,682 in stock - Investing.com
Ventyx Biosciences' chief scientific officer sells $29,682 in stock By Investing.com - Investing.com UK
Insiders Enjoy US$190k Return After Buying Ventyx Biosciences Stock - Simply Wall St
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Ventyx Biosciences Insiders Land Bargain With Gains Of US$180k - Yahoo Finance
VENTYX ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Cryopyrin-associated Periodic Syndromes Market on Track for Major Expansion by 2034, According to DelveInsight | Amgen, Biovitrum, Novartis, Ventyx Biosciences - The Globe and Mail
Neurogene and Ventyx Biosciences rises after insider buying by executives - MSN
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Bought by Vestal Point Capital LP - MarketBeat
Sio Capital Management LLC Raises Stock Holdings in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - MarketBeat
Hedge Fund and Insider Trading News: Bill Ackman, Paul Tudor Jones, Whitney Tilson, Steven Cohen, Scott Bessent, Millennium Management, Paloma Partners, Ventyx Biosciences Inc (VTYX), Vistra Corp (VST), and More - Insider Monkey
Ventyx Biosciences Inc (NASDAQ: VTYX) Jumps 11.35%, Turning Investors Away - Stocks Register
Ventyx Biosciences CEO Mohan Raju buys $959,889 in stock By Investing.com - Investing.com Nigeria
Ventyx Biosciences CEO Mohan Raju buys $959,889 in stock - Investing.com
Analysts Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) Price Target at $10.00 - MarketBeat
Ventyx Biosciences Inc (VTYX) 財務データ
収益
当期純利益
現金流量
EPS
5.49%
0.79%
大文字化:
|
ボリューム (24 時間):